Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health, Pfizer Collaborate on Prognostic Renal Carcinoma Test

This article has been updated from a previous version, which incorrectly described the test as predictive instead of prognostic.
NEW YORK (GenomeWeb News) - Genomic Health said today it will work with Pfizer to develop a genomic test to estimate the risk of post-surgery recurrence of a carcinoma.
Genomic Health, working with Pfizer, will use the same technology it uses in its Oncotype Dx breast cancer recurrence test to create the prognostic test for patients with stage I-III renal carcinoma, clear cell type, if the disease has not spread to other parts of the body.
"Many early-stage renal carcinoma patients experience a recurrence of their cancer, yet there is no accurate way to identify the most aggressive cancers in advance,” Genomic Health’s VP of business development, Chu Chang, said in a statement.
"Working together with Pfizer, we have the potential to address a serious unmet need," Chang added.
Financial terms of the agreement were not provided.
News of the agreement gave Genomic Health shares a boost. In mid-afternoon trading, the company’s stock was up 6.16 percent, to $22.75.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.